The bluest of blue chip stocks, health care conglomerate Johnson & Johnson (NYSE: JNJ), reported strong second quarter results and yet shares tumbled almost 2%.

Operationally J&J couldn't have been stronger; growing its topline 9% to 19.5 billion, and excluding one-time items, embarrassing Wall St earnings estimates at $1.66 per share, 11 cents better than expected. The pharma division continues its streak of monster growth, clocking in 21% gains, while its Medical Devices and Consumer segments chipped in strong international performances.

However, despite its recent success, J&J's full year guidance may be the culprit for its troubles on the market today.

In this special edition of Market Checkup, health care analysts David Williamson and Michael Douglass focus exclusively on J&J's second quarter results. Watch and find out everything worth knowing about the stock and how investors should react to its earnings.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


David Williamson owns shares of Johnson & Johnson. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Compare Brokers